Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

Apogee Therapeutics, Inc.

PIPELINE PROGRAMS CONTINUE TO ADVANCE, WITH FOUR CLINICAL DATA READOUTS ANTICIPATED IN 2026; APG777 TRIAL READOUT TIMELINES ACCELERATED, WITH PHASE 1B IN ASTHMA AND APEX 52-WEEK PART A DATA IN AD ANTICIPATED IN Q1 2026, APEX 16-WEEK PART B DATA IN AD IN Q2 2026, AND APG279 PHASE 1B HEAD-TO-HEAD READOUT AGAINST DUPIXENT IN AD IN 2H 2026

APOGEE THERAPEUTICS PROVIDES PIPELINE PROGRESS AND REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

INTERIM PHASE 1 RESULTS FOR APG333 EXCEEDED TRIAL OBJECTIVES, DEMONSTRATED A HALF-LIFE OF APPROXIMATELY 55 DAYS, AND SUPPRESSED KEY BIOMARKERS FOR 6 MONTHS FOLLOWING A SINGLE DOSE, SUPPORTING POTENTIAL 3- AND 6- MONTH DOSING

APOGEE THERAPEUTICS ANNOUNCES POSITIVE INTERIM PHASE 1 RESULTS FROM HEALTHY VOLUNTEER TRIAL OF APG333, ITS NOVEL HALF-LIFE EXTENDED TSLP ANTIBODY

SAN FRANCISCO AND BOSTON, NOV. 03, 2025 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC., (NASDAQ: APGE), TODAY ANNOUNCED THAT MEMBERS OF MANAGEMENT WILL PARTICIPATE AT THE FOLLOWING INVESTOR CONFERENCES. GUGGENHEIM 2 ND ANNUAL HEALTHCARE INNOVATION CONFERENCE DATE:TUESDAY, NOVEMBER 11, 2025FIRESIDE CHAT TIME:1:30 P.M.

APOGEE THERAPEUTICS TO PARTICIPATE IN UPCOMING CONFERENCES

SAN FRANCISCO AND BOSTON, OCT. 10, 2025 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC. (NASDAQ: APGE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING OPTIMIZED, NOVEL BIOLOGICS WITH POTENTIAL FOR BEST-IN-CLASS PROFILES IN THE LARGEST INFLAMMATORY AND IMMUNOLOGY (I&I) MARKETS, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 8,048,782 SHARES OF ITS COMMON STOCK, INCLUDING THE FULL EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE UP TO 1,097,561 ADDITIONAL SHARES, AT A PUBLIC OFFERING PRICE PER SHARE OF $41.00 AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE UP TO 365,853 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $40.99999 PER PRE-FUNDED WARRANT. THE PRE-FUNDED WARRANTS HAVE AN EXERCISE PRICE OF $0.00001 PER SHARE AND ARE EXERCISABLE IMMEDIATELY. THE AGGREGATE GROSS PROCEEDS TO APOGEE FROM THE OFFERING WERE APPROXIMATELY $345 MILLION BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES PAYABLE BY APOGEE.

APOGEE THERAPEUTICS, INC. ANNOUNCES CLOSING OF PUBLIC OFFERING AND FULL EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES FOR GROSS PROCEEDS OF $345 MILLION

SAN FRANCISCO AND BOSTON, OCT. 08, 2025 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC. (NASDAQ: APGE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING OPTIMIZED, NOVEL BIOLOGICS WITH POTENTIAL FOR BEST-IN-CLASS PROFILES IN THE LARGEST INFLAMMATORY AND IMMUNOLOGY (I&I) MARKETS, TODAY ANNOUNCED THE PRICING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 6,951,221 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE PER SHARE OF $41.00 AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE UP TO 365,853 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $40.99999 PER PRE-FUNDED WARRANT. THE PRE-FUNDED WARRANTS HAVE AN EXERCISE PRICE OF $0.00001 PER SHARE AND ARE EXERCISABLE IMMEDIATELY. THE AGGREGATE GROSS PROCEEDS TO APOGEE FROM THE OFFERING ARE EXPECTED TO BE APPROXIMATELY $300 MILLION BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES PAYABLE BY APOGEE, EXCLUDING ANY EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES. THE OFFERING IS EXPECTED TO CLOSE ON OCTOBER 10, 2025, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS. IN ADDITION, APOGEE HAS GRANTED THE UNDERWRITERS AN OPTION FOR A PERIOD OF 30 DAYS TO PURCHASE UP TO AN ADDITIONAL 1,097,561 SHARES OF ITS COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS.

APOGEE THERAPEUTICS, INC. ANNOUNCES PRICING OF $300 MILLION UNDERWRITTEN PUBLIC OFFERING

SAN FRANCISCO AND BOSTON, OCT. 08, 2025 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC. (NASDAQ: APGE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING OPTIMIZED, NOVEL BIOLOGICS WITH POTENTIAL FOR BEST-IN-CLASS PROFILES IN THE LARGEST INFLAMMATORY AND IMMUNOLOGY (I&I) MARKETS, TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF SHARES OF ITS COMMON STOCK OR, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS THAT SO CHOOSE, PRE-FUNDED WARRANTS TO PURCHASE SHARES OF ITS COMMON STOCK. IN ADDITION, APOGEE EXPECTS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 15% OF THE SHARES OF ITS COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. THE PROPOSED PUBLIC OFFERING IS SUBJECT TO MARKET AND OTHER CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING. ALL OF THE SECURITIES ARE BEING OFFERED BY APOGEE.

APOGEE THERAPEUTICS, INC. ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING

SAN FRANCISCO AND BOSTON, SEPT. 11, 2025 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC., (NASDAQ: APGE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING OPTIMIZED, NOVEL BIOLOGICS WITH POTENTIAL FOR BEST-IN-CLASS PROFILES IN THE LARGEST INFLAMMATORY AND IMMUNOLOGY (I&I) MARKETS, TODAY ANNOUNCED DATA FROM THE PHASE 2 APEX TRIAL OF APG777 FOR MODERATE-TO-SEVERE ATOPIC DERMATITIS WAS ACCEPTED FOR A LATE-BREAKER ORAL PRESENTATION AT THE UPCOMING EADV CONGRESS 2025, TO BE HELD IN PARIS, FRANCE FROM SEPTEMBER 17-20, 2025. THE COMPANY WILL ALSO PRESENT MULTIPLE POSTER PRESENTATIONS HIGHLIGHTING APG777'S BEST-IN-CLASS POTENTIAL INCLUDING DATA SUPPORTING ITS COMBINATION STRATEGY.

APOGEE THERAPEUTICS ANNOUNCES LATE-BREAKER PRESENTATION OF 16-WEEK DATA FROM PHASE 2 APEX TRIAL OF APG777 FOR MODERATE-TO-SEVERE ATOPIC DERMATITIS AT THE UPCOMING EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (EADV) 2025 CONGRESS

SAN FRANCISCO AND BOSTON, SEPT. 03, 2025 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC., (NASDAQ: APGE), TODAY ANNOUNCED THAT MEMBERS OF MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE STIFEL 2025 VIRTUAL IMMUNOLOGY AND INFLAMMATION FORUM ON TUESDAY, SEPTEMBER 16, 2025, AT 11:30 A.M. E.T.

APOGEE THERAPEUTICS TO PARTICIPATE AT THE STIFEL 2025 VIRTUAL IMMUNOLOGY AND INFLAMMATION FORUM

POSITIVE 16-WEEK DATA FROM APEX PHASE 2 PART A MET ALL PRIMARY AND KEY SECONDARY ENDPOINTS FOR APG777, A POTENTIALLY BEST-IN-CLASS ANTI-IL-13 ANTIBODY, IN MODERATE-TO-SEVERE ATOPIC DERMATITIS

APOGEE THERAPEUTICS PROVIDES PIPELINE PROGRESS AND REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

APEX PART A MET ALL PRIMARY AND KEY SECONDARY ENDPOINTS AND EXCEEDED TRIAL OBJECTIVES, INCLUDING 7 1.0% DECREASE FROM BASELINE IN EASI AT WEEK 16

APOGEE THERAPEUTICS ANNOUNCES POSITIVE 16-WEEK DATA FROM PHASE 2 APEX CLINICAL TRIAL OF APG777, ITS POTENTIALLY BEST-IN-CLASS ANTI-IL-13 ANTIBODY, IN MODERATE-TO-SEVERE ATOPIC DERMATITIS

Apogee Therapeutics, Inc.

APGE

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Apogee Therapeutics, Inc.

APGE.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

APGE